SCHEMBL3018834

SCHEMBL3018834

Cc1ccc(S(=O)(=O)C2CCN(c3nc(-c4ccc(Cl)cc4Cl)cs3)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.56
SMN1; SMN2 Q16637 4/20 0.45
MAPT P10636 4/20 0.45
NPSR1 Q6W5P4 3/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2C9 P11712 2/20 0.45
HPGD P15428 2/20 0.45
CYP2C19 P33261 2/20 0.45
ALDH1A1 P00352 2/20 0.45
POLB P06746 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 1/20 0.45
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
GBA1 P04062 1/20 0.41
MAOA P21397 3/20 0.40
MAOB P27338 3/20 0.40
RORC P51449 1/20 0.40
LMNA P02545 3/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017157 0.94 AR (0.60) ARSMN1; SMN2MAPTNPSR1CYP1A2
SCHEMBL3002708 0.90 AR (0.56) ARSMN1; SMN2MAPTNPSR1CYP1A2
SCHEMBL3002625 0.90 AR (0.56) ARSMN1; SMN2MAPTNPSR1CYP1A2
SCHEMBL3021277 0.90 AR (0.60) ARSMN1; SMN2MAPTNPSR1CYP1A2
SCHEMBL3020212 0.90 AR (0.53) ARSMN1; SMN2MAPTNPSR1CYP1A2
SCHEMBL3014549 0.90 AR (0.53) ARSMN1; SMN2MAPTNPSR1ALDH1A1
SCHEMBL3016907 0.89 AR (0.57) ARSMN1; SMN2MAPTNPSR1CYP1A2
SCHEMBL3014452 0.89 AR (0.54) ARSMN1; SMN2MAPTNPSR1CYP1A2
SCHEMBL3008958 0.88 AR (0.53) ARSMN1; SMN2MAPTNPSR1POLB
SCHEMBL3013160 0.87 AR (0.55) ARSMN1; SMN2MAPTNPSR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885SMN1; SMN2 1/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.